Partnership Coordination

The Long-acting Partnerships Strategy was initiated to prioritise partnerships that accelerate achievement of global targets to reduce morbidity and mortality from malaria, hepatitis C virus, tuberculosis, HIV and coinfections / comorbidities. The project incorporates activities that support knowledge sharing to accelerate equitable availability and access to long-acting products in low- and middle- income countries, and on ensuring sustainability and reduction of the environmental footprint associated with research, manufacturing, distribution and delivery.

Project overview

The Long-acting Partnership Strategy brings together four core activities aimed at accelerating the development and equitable uptake of long-acting therapeutics, especially in low- and middle- income countries (LMICs):

The Long-acting Projects Advisory Committee (LAPAC)
A long-acting workshop series
A long-acting annual conference
A long-acting projects dashboard.

The LAPAC (launched in 2020) advises the funder, global health agency Unitaid, and the grantees on research and development, the acceleration of equitable availability and access in LMICs, and on reducing environmental footprints across the long-acting lifecycle.

The workshop series will convene researchers, clinicians, implementers, regulators, manufacturers, funders, and patient advocates to surface evidence and gaps, and share best practice in research and development, manufacturing, delivery, and pharmacovigilance.

The annual conference will align evidence, policy, and market actions so innovation translates into equitable health impact, particularly in LMICs.

Finally, the dashboard will give researchers, regulators, patient advocates, procurement agencies, and programme managers a curated global view of who is doing what, where, and on what timelines to support coordinated decision-making.

CELT's objectives

Facilitate the exchange of updates and information on the relevant aspects of the long-acting landscape
Facilitate development of collaborative working relationships with stakeholder groups
Platform and engaging with LMIC stakeholders
Promote visibility of long-acting LMIC orientated projects throughout academia and industry
Provide reporting and a means of sharing metrics to help promote progress and learning.

LA-LINK

We host a seminar and workshop series designed to bring together researchers, developers, policymakers, funders, and implementers working across the rapidly evolving field of long-acting therapeutics.

Long-acting medicines and technologies are transforming prevention and treatment for a range of conditions that disproportionately affect people in low- and middle- income countries (LMICs). As the field advances, so does the need for accessible medicines, and LA-LINK aims to be a cross-stakeholder learning space where expertise can be shared, challenges identified, and new collaborations connected.

What is LA-LINK?

LA-LINK (Long-acting Learning, Innovation, Networks and Knowledge) is a recurring online seminar and workshop series hosted by the Centre of Excellence for Long-Acting Therapeutics (CELT). Each session will feature experts from across academia, industry, global health organisations, and regulatory bodies, sharing insights on the science, strategy, and implementation of long-acting technologies.

Why Now?

The long-acting field is expanding, with new technologies, regulatory pathways, and platforms are emerging, but knowledge often sits in silos and bottlenecks can sometimes be discovered late in a project/product lifecycle. By creating a regular convening point, LA-LINK will help:

Highlight cutting-edge research, technology and innovation
Share lessons learned across disease areas and geographies
Strengthen connections between global partners and reveal new potential opportunities for partnership and pilot programmes
Support evidence-based decision-making for long-acting products in development and deployment

What to expect

Each webinar will feature:

Focused expert talks or panels
Space for questions and answers and community discussion
Session summaries and materials shared afterward

Topics will include long-acting formulations, regulatory considerations, modelling, PK, clinical trial design manufacturing, PPI, access, emerging technologies, public-private partnerships, operational research, and more.

We hope that LA-LINK will become a resource of information and will lead to practical takeaways for developers, policymakers, and programme leads

Upcoming session(s)

The first LA-LINK session will be ‘Application of pharmacokinetic modelling and simulation for long-acting medicines’.

Please check back for further details on speakers, talks, agenda and registration details as we release them.

Whether you’re deeply embedded in long-acting research or just beginning to explore the field, you’re warmly invited to be part of this growing community via LA-LINK.